<VariationArchive VariationID="1458697" VariationName="NC_000022.10:g.(?_29121102)_(29125325_?)del" VariationType="Deletion" Accession="VCV001458697" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1491046" VariationID="1458697">
      <GeneList>
        <Gene Symbol="CHEK2" FullName="checkpoint kinase 2" GeneID="11200" HGNC_ID="HGNC:16627" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q12.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="28687743" stop="28741834" display_start="28687743" display_stop="28741834" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="29083730" stop="29137821" display_start="29083730" display_stop="29137821" Strand="-" />
          </Location>
          <OMIM>604373</OMIM>
          <Haploinsufficiency last_evaluated="2020-01-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CHEK2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-01-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CHEK2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000022.10:g.(?_29121102)_(29125325_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q12.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" innerStart="29121102" innerStop="29125325" display_start="29121102" display_stop="29125325" variantLength="4224" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.(?_29121102)_(29125325_?)del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.(?_29121102)_(29125325_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000022.10:g.(?_29121102)_(29125325_?)del AND Familial cancer of breast" Accession="RCV001975044" Version="5">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-17" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11298456</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11390408</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11571648</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11719428</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12049740</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15239132</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15535844</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16982735</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21876083</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22419737</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24713400</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29356917</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29909963</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4263978" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_007194.3_22_Partial deletion (exons 3-4)_29121101_29125325|MedGen:C0346153" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002246054" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21876083</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24713400</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11298456</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11390408</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11571648</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11719428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12049740</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15239132</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15535844</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16982735</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22419737</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29356917</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29909963</ID>
          </Citation>
          <Comment>This variant results in the deletion of exon 3 and part of exon 4 (c.320-3970_455del) of the CHEK2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CHEK2 are known to be pathogenic (PMID: 21876083, 24713400). This variant has not been reported in the literature in individuals affected with CHEK2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1713222). This variant disrupts the p.Arg145 amino acid residue in CHEK2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11298456, 11390408, 11571648, 11719428, 12049740, 15239132, 15535844, 16982735, 22419737, 29356917, 29909963). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CHEK2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.(?_29121102)_(29125325_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0346153" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4263978" TraitType="Disease" MappingType="XRef" MappingValue="C0346153" MappingRef="MedGen">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

